MammoWave Device

The first breast test to help change the paradigm of breast cancer prevention

MammoWave Device

Focusing on persons’ well-being, our solution is non-ionizing (free from X-rays), meaning there is no radiation risk

Play Video

Microwave Imaging

MammoWave is made of an aluminium cylindrical hub, containing two antennas that operate in the microwave band (1-9 GHz) at a very low power (1mW). MammoWave allows to illuminate the breast using an electromagnetic fields and to measure the correspondent scattered fields. The measured fields is then processed field through a dedicated algorithm, obtaining the image of the breast. Microwave imaging exploits the contrast in the dielectric properties at microwave frequencies of normal tissues and tissues with lesions. MammoWave software uses a novel, fast, and accurate imaging algorithm (based on the Huygens Principle) which highlights tissues dielectric inhomogeneities.

MammoWave benefits

Accuracy

MammoWave is a highly accurate screening device with high sensitivity and high specificity, regardless of tissue density. MammoWave performance in detecting breast lesions are enhanced through dedicated classification algorithms

Affordability and Simplicity

With low setup and running costs, MammoWave can transform your clinic offering to a more people-centric screening that is innovative and cost-effective. MammoWave 's imagining technology is operator independent

For all women, any time

MammoWave can be used in asymptomatic population without any safety restriction such as age or frequency of use. MammoWave is the perfect solution for a complementary use with respect to traditional devices to assist in reducing the risk of missing lesions in asymptomatic population

Comfort

A breast scan is completed whilst the person is in a horizontal face down position on a thin mattress, with each breast, in turn, placed in a soft cup. MammoWave removes the need for applying pressure on the breast or any liquid to be applied, making it a painless, dry and comfortable experience for the person

Clinical Trials

MammoWave is validated by a feasibility clinical trial and three international prospective multicenter clinical trials (over 5,000 women in total – June 2025):

Feasibility clinical trial conducted on 150 women (both asymptomatic and symptomatic) at the Hospitals of Perugia and Foligno, Italy. Completed.
Prospective sponsored clinical trial on 353 women (both asymptomatic and symptomatic), activated thanks to an EU-funded grant under H2020-SME-Instrument-Phase2 (GA: 830265). Completed in 3 European hospitals. https://clinicaltrials.gov/ct2/show/NCT04253366
Prospective sponsored clinical trial on 600 women (both asymptomatic and symptomatic), activated thanks to a grant funded by the EU under FUTURE EMERGING TECHNOLOGIES (FET) H2020 – FETPROACT (GA: 101017098). Ongoing in 3 European hospitals. https://clinicaltrials.gov/ct2/show/NCT05300464
Prospective sponsored clinical trial on 10,000 asymptomatic women, activated thanks to a grant funded by the EU under HORIZON-MISS-2021-CANCER-02-01 (GA: 101097079, Project: MammoScreen, https://mammoscreenproject.eu/ ). Ongoing in 10 European hospitals. https://clinicaltrials.gov/ct2/show/NCT06291896

The results of the clinical trials, the images of some test cases and the description of the performances can be found on our page: Publications.